Clinical Trials in Spokane, WA

Browse 100 Clinical Trials Spokane Across 875 Cities
54 Phase 3 Trial · 4856 Clinical Trials Spokane Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Clinical Trials in Spokane, WA

Reviewed by Michael Gill, B. Sc.

Image of Clinical Site in Port Orange, United States.

10 Clinical Trials Spokane Near Me

Top Cities for Clinical Trials Spokane

New York

85Active Trials

Memorial Sloan Kettering Cancer CenterTop Active Site

Spokane

84Active Trials

Providence Sacred Heart Medical Center and Children's HospitalTop Active Site

Clinical Trials Spokane by Phase of Trial

N/A Clinical Trials Spokane

12Active Clinical Trials Spokane

12Number of Unique Treatments

609Number of Active Locations

Treatment Arm prodisc C SK and/or Vivo Resin microspheres containing yttrium-90 (Y-90)Treatment Investigational LUX-Dx ICM Implant regional nodal XRT MPC Arm Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)Pembrolizumab Shaping CM Edwards SAPIEN 3 / SAPIEN 3 Ultra THV Triathlon Tritanium Cone Augments

Most Recent Clinical Trials Spokane

Clinical Trial

Began Recruiting Date

Phase

Durvalumab + BCG for Bladder Cancer

8/11/2023

Phase 3

ZL-1218 for Cancer

7/24/2023

Phase 1

Period 1: Upadacitinib Dose A for Hidradenitis Suppurativa

6/21/2023

Phase 3

Cohort 1 for Cachexia

6/13/2023

Phase 1

Higher Dose Regimen 1 for Macular Edema

5/15/2023

Phase 3

About The Author

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: August 13th, 2023

References¹ Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/31401903² Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/31401903³ Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27. Review. https://pubmed.ncbi.nlm.nih.gov/23014338⁴ Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol. 2003 Apr;68(2):111-20. Review. https://pubmed.ncbi.nlm.nih.gov/12866702⁵ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. https://pubmed.ncbi.nlm.nih.gov/34406619⁶ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Nov;22(6):905. https://pubmed.ncbi.nlm.nih.gov/34406619⁷ Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33. doi: 10.1159/000365390. Epub 2015 Jan 20. https://pubmed.ncbi.nlm.nih.gov/25613671⁸ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Oct 13;:. https://pubmed.ncbi.nlm.nih.gov/34406619⁹ Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum In: Am J Clin Dermatol. 2021 Nov;22(6):905. https://pubmed.ncbi.nlm.nih.gov/34406619¹⁰ Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol. 2008 Jul;128(7):1728-36. doi: 10.1038/sj.jid.5701239. Epub 2008 Jan 17. https://pubmed.ncbi.nlm.nih.gov/18200056